JP2013545745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545745A5 JP2013545745A5 JP2013538326A JP2013538326A JP2013545745A5 JP 2013545745 A5 JP2013545745 A5 JP 2013545745A5 JP 2013538326 A JP2013538326 A JP 2013538326A JP 2013538326 A JP2013538326 A JP 2013538326A JP 2013545745 A5 JP2013545745 A5 JP 2013545745A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- levodopa
- arginine
- carbidopa
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 36
- 239000004475 Arginine Substances 0.000 claims 35
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 35
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 32
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 32
- 229960004502 levodopa Drugs 0.000 claims 32
- 229960004205 carbidopa Drugs 0.000 claims 30
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 30
- 235000010323 ascorbic acid Nutrition 0.000 claims 18
- 239000011668 ascorbic acid Substances 0.000 claims 18
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 16
- 229960003194 meglumine Drugs 0.000 claims 16
- 229960005070 ascorbic acid Drugs 0.000 claims 10
- 239000011734 sodium Substances 0.000 claims 9
- 229940072107 ascorbate Drugs 0.000 claims 8
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960003180 glutathione Drugs 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000004260 Potassium ascorbate Substances 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 235000010376 calcium ascorbate Nutrition 0.000 claims 1
- 229940047036 calcium ascorbate Drugs 0.000 claims 1
- 239000011692 calcium ascorbate Substances 0.000 claims 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 235000019275 potassium ascorbate Nutrition 0.000 claims 1
- 229940017794 potassium ascorbate Drugs 0.000 claims 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 claims 1
- 235000010378 sodium ascorbate Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
- 229960005055 sodium ascorbate Drugs 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41363710P | 2010-11-15 | 2010-11-15 | |
| US61/413,637 | 2010-11-15 | ||
| US201161524064P | 2011-08-16 | 2011-08-16 | |
| US61/524,064 | 2011-08-16 | ||
| PCT/IL2011/000881 WO2012066538A1 (en) | 2010-11-15 | 2011-11-15 | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016047187A Division JP6231145B2 (ja) | 2010-11-15 | 2016-03-10 | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013545745A JP2013545745A (ja) | 2013-12-26 |
| JP2013545745A5 true JP2013545745A5 (enExample) | 2014-12-04 |
| JP5902705B2 JP5902705B2 (ja) | 2016-04-13 |
Family
ID=45478410
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538326A Active JP5902705B2 (ja) | 2010-11-15 | 2011-11-15 | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
| JP2016047187A Active JP6231145B2 (ja) | 2010-11-15 | 2016-03-10 | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
| JP2017201780A Active JP6387171B2 (ja) | 2010-11-15 | 2017-10-18 | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016047187A Active JP6231145B2 (ja) | 2010-11-15 | 2016-03-10 | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
| JP2017201780A Active JP6387171B2 (ja) | 2010-11-15 | 2017-10-18 | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US9421267B2 (enExample) |
| EP (3) | EP3692982A1 (enExample) |
| JP (3) | JP5902705B2 (enExample) |
| KR (1) | KR101859242B1 (enExample) |
| CN (2) | CN110123743A (enExample) |
| AU (1) | AU2011330757B2 (enExample) |
| BR (1) | BR112013011685B1 (enExample) |
| CA (1) | CA2817888C (enExample) |
| CL (1) | CL2013001368A1 (enExample) |
| CY (1) | CY1120005T1 (enExample) |
| DK (2) | DK3326615T3 (enExample) |
| ES (2) | ES2776734T3 (enExample) |
| HR (2) | HRP20180514T1 (enExample) |
| HU (2) | HUE037005T2 (enExample) |
| IL (1) | IL263954A (enExample) |
| LT (1) | LT2640358T (enExample) |
| MX (1) | MX348225B (enExample) |
| NZ (1) | NZ610911A (enExample) |
| PL (2) | PL3326615T3 (enExample) |
| PT (2) | PT2640358T (enExample) |
| RS (1) | RS57047B1 (enExample) |
| RU (2) | RU2740080C2 (enExample) |
| SG (2) | SG10201509316SA (enExample) |
| SI (1) | SI2640358T1 (enExample) |
| SM (1) | SMT201800145T1 (enExample) |
| WO (1) | WO2012066538A1 (enExample) |
| ZA (1) | ZA201303509B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201505101VA (en) | 2009-05-19 | 2015-07-30 | Neuroderm Ltd | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
| SI2640358T1 (en) | 2010-11-15 | 2018-05-31 | Neuroderm Ltd. | Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof |
| ES2673219T3 (es) | 2010-11-15 | 2018-06-20 | Neuroderm Ltd | Composición para la entrega transdérmica de agentes activos |
| AU2013273138B2 (en) | 2012-06-05 | 2017-06-15 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| CN105209029A (zh) * | 2013-03-13 | 2015-12-30 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| WO2015115512A1 (ja) | 2014-01-29 | 2015-08-06 | 独立行政法人産業技術総合研究所 | シクロデキストリンの利用による抗がん活性が増強されたアシュワガンダ葉の水抽出物の調製方法、及びアシュワガンダ葉を含む医薬組成物 |
| WO2015136538A1 (en) * | 2014-03-13 | 2015-09-17 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| CA3175785A1 (en) | 2014-09-04 | 2016-03-10 | Intrance International Ab | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| RU2021103000A (ru) | 2014-10-21 | 2021-03-01 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| CA3019382A1 (en) | 2015-03-30 | 2016-10-06 | Berlirem Gmbh | Water-soluble l-dopa esters |
| DK3075723T3 (en) | 2015-03-30 | 2017-09-11 | Berlirem Gmbh | High-resolution L-DOPA glycerol esters |
| WO2016179540A1 (en) | 2015-05-06 | 2016-11-10 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| WO2017039525A1 (en) * | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| JP2019515908A (ja) * | 2016-04-20 | 2019-06-13 | アッヴィ・インコーポレイテッド | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| CN106619490A (zh) * | 2017-01-19 | 2017-05-10 | 云南白药集团无锡药业有限公司 | 一种左旋多巴透皮贴剂及其制备方法 |
| HRP20210599T1 (hr) * | 2017-06-05 | 2021-05-14 | Dizlin Pharmaceuticals Ab | Otopina levodope za infuziju |
| RS63324B1 (sr) | 2017-07-07 | 2022-07-29 | Neuroderm Ltd | Uređaj za potkožnu isporuku tečnih lekova |
| HRP20251502T1 (hr) | 2018-03-23 | 2026-02-13 | Lobsor Pharmaceuticals Aktiebolag | Kontinuirana primjena farmaceutskog pripravka za liječenje neurodegenerativnih poremećaja |
| EP3880210A1 (en) | 2018-11-15 | 2021-09-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| JP2023538859A (ja) * | 2020-08-31 | 2023-09-12 | パーデュー、ファーマ、リミテッド、パートナーシップ | レボドパ送達のための組成物及び方法 |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| IL314066A (en) * | 2022-01-03 | 2024-09-01 | Neuroderm Ltd | Methods and compositions for treating parkinson's disease |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808317A (en) * | 1969-10-29 | 1974-04-30 | Alcon Labor Inc | Stabilized aqueous borate complexes of biologically active catechol amines |
| US3936495A (en) | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (ja) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| EP0252290B1 (en) | 1986-06-10 | 1992-06-03 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof |
| US4684666A (en) | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| WO1992007561A1 (en) | 1990-10-30 | 1992-05-14 | Ss Pharmaceutical Co., Ltd. | Antiphlogistic and analgesic gel preparation |
| US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| AU1917899A (en) | 1998-03-20 | 1999-10-18 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| HU228771B1 (en) | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| US6274168B1 (en) | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2000054773A1 (en) | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| AU2002220977A1 (en) * | 2000-12-15 | 2002-06-24 | Pfizer Inc. | Treatment of male sexual dysfunction |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| AU2002357137A1 (en) | 2001-12-10 | 2003-06-23 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| EP1496868A1 (en) | 2002-04-11 | 2005-01-19 | Ranbaxy Laboratories, Ltd. | Controlled release pharmaceutical compositions of carbidopa and levodopa |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| DE10247233A1 (de) * | 2002-10-10 | 2004-06-17 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen, die Topoisomerase IV inhibieren |
| BR0315221A (pt) * | 2002-10-10 | 2005-08-23 | Morphochem Ag Komb Chemie | Compostos com atividade antibacteriana |
| BRPI0412735A (pt) | 2003-07-18 | 2006-09-26 | Baxter Int | métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| US20050053669A1 (en) * | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| JP2007509973A (ja) | 2003-10-31 | 2007-04-19 | アルザ・コーポレーシヨン | 増強された吸収のための組成物および投与形態物 |
| WO2005099678A1 (en) * | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| ES2572811T3 (es) | 2004-09-09 | 2016-06-02 | Yeda Research And Development Co., Ltd. | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos |
| WO2006037061A2 (en) | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| CA2582346A1 (en) * | 2004-10-01 | 2006-04-13 | The Research Foundation Of State University Of New York | Morphine and morphine precursors |
| DE102006021872B4 (de) * | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR20090057349A (ko) * | 2006-05-31 | 2009-06-05 | 솔베이 파머슈티컬스 게엠베하 | 레보도파／칼비도파의 ２４시간의 장기간 장내투여 |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| CA2682888A1 (en) | 2007-04-06 | 2008-10-16 | Transform Pharmaceuticals, Inc. | Systems and methods for delivering a fluid drug |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| SG10201505101VA (en) | 2009-05-19 | 2015-07-30 | Neuroderm Ltd | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| SI2640358T1 (en) | 2010-11-15 | 2018-05-31 | Neuroderm Ltd. | Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof |
| ES2673219T3 (es) | 2010-11-15 | 2018-06-20 | Neuroderm Ltd | Composición para la entrega transdérmica de agentes activos |
| SG191090A1 (en) | 2010-12-10 | 2013-07-31 | Synagile Corp | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| US20130116215A1 (en) | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
| CN105209029A (zh) | 2013-03-13 | 2015-12-30 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| WO2015136538A1 (en) | 2014-03-13 | 2015-09-17 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
-
2011
- 2011-11-15 SI SI201131440T patent/SI2640358T1/en unknown
- 2011-11-15 EP EP20150020.4A patent/EP3692982A1/en not_active Withdrawn
- 2011-11-15 EP EP11808359.1A patent/EP2640358B1/en active Active
- 2011-11-15 CN CN201910369050.XA patent/CN110123743A/zh active Pending
- 2011-11-15 SM SM20180145T patent/SMT201800145T1/it unknown
- 2011-11-15 EP EP17207731.5A patent/EP3326615B1/en active Active
- 2011-11-15 RS RS20180386A patent/RS57047B1/sr unknown
- 2011-11-15 RU RU2016147575A patent/RU2740080C2/ru active
- 2011-11-15 KR KR1020137015306A patent/KR101859242B1/ko active Active
- 2011-11-15 CA CA2817888A patent/CA2817888C/en active Active
- 2011-11-15 US US13/885,518 patent/US9421267B2/en active Active
- 2011-11-15 ES ES17207731T patent/ES2776734T3/es active Active
- 2011-11-15 ES ES11808359.1T patent/ES2660772T3/es active Active
- 2011-11-15 SG SG10201509316SA patent/SG10201509316SA/en unknown
- 2011-11-15 PT PT118083591T patent/PT2640358T/pt unknown
- 2011-11-15 JP JP2013538326A patent/JP5902705B2/ja active Active
- 2011-11-15 SG SG2013036678A patent/SG190258A1/en unknown
- 2011-11-15 MX MX2013005493A patent/MX348225B/es active IP Right Grant
- 2011-11-15 NZ NZ610911A patent/NZ610911A/en not_active IP Right Cessation
- 2011-11-15 WO PCT/IL2011/000881 patent/WO2012066538A1/en not_active Ceased
- 2011-11-15 LT LTEP11808359.1T patent/LT2640358T/lt unknown
- 2011-11-15 CN CN2011800648945A patent/CN103442693A/zh active Pending
- 2011-11-15 RU RU2013123457A patent/RU2607497C2/ru active
- 2011-11-15 DK DK17207731.5T patent/DK3326615T3/da active
- 2011-11-15 BR BR112013011685-4A patent/BR112013011685B1/pt active IP Right Grant
- 2011-11-15 DK DK11808359.1T patent/DK2640358T3/en active
- 2011-11-15 HU HUE11808359A patent/HUE037005T2/hu unknown
- 2011-11-15 AU AU2011330757A patent/AU2011330757B2/en active Active
- 2011-11-15 PT PT172077315T patent/PT3326615T/pt unknown
- 2011-11-15 PL PL17207731T patent/PL3326615T3/pl unknown
- 2011-11-15 HR HRP20180514TT patent/HRP20180514T1/hr unknown
- 2011-11-15 PL PL11808359T patent/PL2640358T3/pl unknown
- 2011-11-15 HU HUE17207731A patent/HUE047841T2/hu unknown
-
2013
- 2013-05-15 CL CL2013001368A patent/CL2013001368A1/es unknown
- 2013-05-30 ZA ZA2013/03509A patent/ZA201303509B/en unknown
-
2014
- 2014-04-02 US US14/243,638 patent/US9040578B2/en active Active
- 2014-04-02 US US14/243,625 patent/US9040577B2/en active Active
-
2016
- 2016-03-10 JP JP2016047187A patent/JP6231145B2/ja active Active
- 2016-07-13 US US15/209,423 patent/US20170157077A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017201780A patent/JP6387171B2/ja active Active
-
2018
- 2018-03-06 CY CY20181100276T patent/CY1120005T1/el unknown
- 2018-12-24 IL IL263954A patent/IL263954A/en unknown
-
2020
- 2020-01-22 US US16/749,435 patent/US20200397730A1/en not_active Abandoned
- 2020-03-04 HR HRP20200366TT patent/HRP20200366T1/hr unknown
-
2022
- 2022-03-16 US US17/696,243 patent/US20230047523A1/en not_active Abandoned
-
2024
- 2024-04-12 US US18/633,746 patent/US20250114315A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013545745A5 (enExample) | ||
| HRP20200366T1 (hr) | Kontinuirana primjena l-dopa, inhibitora dopa-dekarboksilaze, inhibitora katekol-o-metil-transferaze i njihovih pripravaka | |
| UA107112C2 (uk) | Активатори розчинної гуанілатциклази | |
| JP2013520405A5 (enExample) | ||
| BR112013031033A2 (pt) | composição destinada ao tratamento de diabetes, compreendendo conjugado de insulina de ação prolongada e conjugado de peptídeo insulinotrópico de ação prolongada | |
| RU2015143112A (ru) | Способ лечения болезни паркинсона | |
| JP2017507973A5 (enExample) | ||
| JP2011051993A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| BR112014029016A8 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| WO2007087241A3 (en) | Treatment of ischemic disease using thrombopoietin | |
| JP2017002035A5 (enExample) | ||
| JP2012517449A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| PH12013501117A1 (en) | Novel compound and medical use thereof | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| JP2015516419A5 (enExample) | ||
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| RU2014112324A (ru) | Применение органического соединения для лечения синдрома нунан | |
| CA2964684A1 (en) | Composition for the treatment of conditions involving muscular pain | |
| JP2009515953A5 (enExample) | ||
| RU2011134414A (ru) | Комбинация фульвовой кислоты для лечения различных состояний и болезней | |
| RU2013155270A (ru) | Инденовые производные для применения в лечении воспалительного заболевания кишечника |